Harnessing gene & cell therapy to end the HIV epidemic.

Our story begins with the recognition of a global crisis: the HIV epidemic.

Since the early 1980s, the epidemic has inflicted unimaginable pain, claiming the lives of over 40 million people worldwide.

To address this formidable challenge, we are pioneering a new generation of gene and cell based therapies, with the goal of delivering what was once thought impossible: a functional cure for HIV.

HIV Epidemic

Cell & Gene Therapy

Dr. Marcus Conant lookout out a window, with an image of his younger self in the background
“ All the patients I’ve lost are not here. But I am. And as long as I can be here to help fight this disease in their name, that’s fulfillment.

Marcus Conant, MD, Chief Medical Officer

Our core beliefs.

Respect

We are deeply committed to the well-being and dignity of those affected by HIV/AIDS. With a profound understanding of the human aspect of our work, we embrace empathy and compassion towards those living with HIV.

Humanity

We recognize that people are more than a diagnosis. Acknowledging the physical, emotional, and social challenges facing individuals living with HIV, we are dedicated to alleviating suffering in communities worldwide.

Diversity

We firmly believe that diversity is the heart of innovation. We wholeheartedly embrace collaborative efforts that propel our knowledge, scientific advancements, and global impact.

Determination

HIV never rests, and neither do we. We are unwavering in our pursuit of fulfilling the promise to end the HIV epidemic and conquer the virus once and for all.

The leadership of American Gene Technologies steers it's HIV-focused division, Addimmune.

Jeff Galvin

CEO of American Gene Technologies™ and it’s HIV-focused division, Addimmune ™

Jeff Galvin

CEO of American Gene Technologies™ and it’s HIV-focused division, Addimmune ™

Jeff Galvin, a visionary biotech leader and entrepreneur, founded American Gene Technologies (AGT), where he serves as CEO, with a mission to pioneer revolutionary gene and cell therapies. AGT, a leading company in the field, focuses on developing potential cures for infectious diseases, cancers, and rare genetic disorders. Galvin’s commitment to innovation led to the establishment of Addimmune, an AGT subsidiary dedicated to finding a functional cure for HIV. With a BA in Economics from Harvard University and a background as a software engineer in Silicon Valley, Galvin’s entrepreneurial journey spans successful tech startups and ventures into medical technology. His multidisciplinary expertise in economics, software, and entrepreneurship drives AGT’s success, positioning the company as a leader in gene and cell therapy innovation.

Jeff Boyle, PhD

Chief Science Officer

Jeff Boyle, PhD

Chief Science Officer

Dr. Jeff Boyle, CSO of Addimmune™, brings over 25 years of expertise in immunology research, assay development, and commercialization. He has held leadership roles in biopharmaceutical and diagnostic companies, including serving as President of Ellume USA LLC, where he established a state-of-the-art manufacturing facility for COVID-19 home tests. Jeff has a strong track record, including executive roles at QIAGEN and R&D leadership positions at CSL Ltd. He boasts a prolific research career with 30 publications and a portfolio of patents in vaccines, immuno-oncology, and medical devices. Jeff is skilled in managing IP assets, strategic initiatives, and product development related to diagnostics, immune stimulation, and oncology therapies.

Marcus Conant, MD

Chief Medical Officer

Marcus Conant, MD

Chief Medical Officer

Dr. Marcus Conant, an early pioneer in HIV patient care during the 1980s, ran the inpatient dermatology service at the University of California San Francisco. Recognizing the impending global epidemic, he founded the Kaposi’s Sarcoma Research & Education Foundation in 1982, later evolving into the San Francisco AIDS Foundation. Despite staggering early mortality rates, he conducted crucial clinical trials. Beyond clinical care, Marcus’s holistic approach extended to education, research, and advocacy. He is now a clinical professor emeritus at the University of California Medical Center and a prolific author, testifying before Congress and advocating for the LGBTQ community.

Drew Palin, MD

President

Drew Palin, MD

President

Drew Palin, MD, is a seasoned entrepreneur known for successfully launching and growing innovative ventures at the intersection of medicine and technology. He’s led over seven startups, generating multi-million-dollar revenues and raising $20M in funding. In various roles, including CEO, CMO, and CIO, he combines vision, personal integrity, and trust to turn untested concepts into thriving businesses. Notable achievements include ThinkMed (acquired by HealthEdge), Preventice (acquired by Boston Scientific), and Intellivisit, which merges AI-driven medical interviews and documentation.

Drew, a board-certified Family Practice Medicine specialist, has a rich clinical background, including working as a physician with the U.S. Men’s Olympic Speed Skating Gold Medalists and inventing sports equipment. His leadership extends to board positions and medical angel investments. Drew is a graduate of Stanford University and Mayo Medical School. 

Lola Liao, CPA

Director of HR & Admin

Lola Liao, CPA

Director of HR & Admin

Lola Liao, CPA, serves as the Director of HR & Administration at Addimmune, overseeing diverse responsibilities ranging from accounting and finance to human resources and office operations. She is a Certified Public Accountant in Maryland with a BS in accounting from the University of Maryland (College Park). Lola previously held roles in finance and accounting at organizations like the Council for Interior Design Qualification, Inc., Comtech Micro System, Inc., and Solarism Display Inc.

Andrew Miller, CPA

VP of Finance

Andrew Miller, CPA

VP of Finance

Andrew has more than 20 years of experience in accounting, finance, strategy, raising capital, and corporate governance in both private companies and non-profit organizations.
Prior to joining AGT, Andrew was Controller for Defenders of Wildlife (Washington, D.C.); Accounting Director at the American Society for Engineering Education (Washington, D.C.); and an Investment Advisor Representative with Raymond James Financial Services, Inc. (Rockville, Maryland).

Andrew earned a bachelor of science degree in business administration with a concentration in finance from Towson University in Maryland. He is currently a Certified Public Accountant (CPA) and was previously registered with Raymond James Financial Services, Inc. (member FINRA/SIPC) as a General Securities Registered Representative (Series 7).

Barry Wells, MD

Head of Business Development

Barry Wells, MD

Head of Business Development

Barry Wells, M.D., spent almost 40 years as a urologist and surgeon, specializing in treating kidney stones, urinary tract infections, and urological conditions. Transitioning his focus to gene therapy, he joined Addimmune™, initially contributing to the investor relations team for three years before becoming the Head of Business Development. With a strong belief in the company’s potential to deliver vital cures, Dr. Wells merges his medical background with a keen interest in business and technology. He has established small-business ventures and raised funds for an early-stage AI company, New Sapience. Dr. Wells graduated with honors from the University of Kansas and obtained his M.D. from the Kansas University School of Medicine, followed by a residency in urologic surgery at the University of Maryland Medical Center.

General Advisors

Tommy Thompson

Advisor

Scientific Advisors

Robert Redfield, MD

Scientific Advisor

Charles Flexner, MD

Scientific Advisor

Michael Saag, MD

Scientific Advisor

Fred Nyberg, PhD

Scientific Advisor

HIV Science Advisors

W. David Hardy, MD

Scientific Advisor

John J. Rossi, PhD

Scientific Advisor

Ely Benaim, MD

HIV Science Advisor

Oncology Science Advisors

Robert Clarke, PhD, DSc

Scientific Advisor

Dean W. Felsher, MD, PhD

Scientific Advisor

PKU Science Advisors

Jerry Vockley, MD, PhD

Scientific Advisor